Axovant Sciences Reports Disappointing Results in Alzheimer’s Trial of Intepirdine

Axovant Sciences Reports Disappointing Results in Alzheimer’s Trial of Intepirdine
Axovant Sciences said its Phase 3 MINDSET clinical trial of the investigational therapy intepirdine did not meet the study's primary goal. In the trial, patients received 35 mg of intepirdine and were assessed at 24 weeks for any changes in cognition scores or measures of daily living, using two tests: ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive Subscale) and ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living). Yet after 24 weeks, patients taking the oral compound showed no significant improvement over those on placebo in either score. However, one key secondary endpoint did show a significant improvement: CIBIC+ (Clinician Interview-Based Impression of Change plus caregiver interview). Intepirdine was als
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *